JOHN MARTIN DOCHERTY - 26 Apr 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
President, Director
Signature
/John Docherty/
Issuer symbol
LEXX
Transactions as of
26 Apr 2024
Net transactions value
$0
Form type
4
Filing time
10 May 2024, 16:34:46 UTC
Previous filing
30 Oct 2023
Next filing
16 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 54,075 26 Apr 2024 Private Holding Company

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +49,500 +40% $0.000000 174,168 26 Apr 2024 Common Shares 49,500 $2.36 Direct
holding LEXX Stock Options 13,334 26 Apr 2024 Common Shares 13,334 $3.00 Direct F1
holding LEXX Stock Options 31,334 26 Apr 2024 Common Shares 18,000 $3.00 Direct F2
holding LEXX Stock Options 49,668 26 Apr 2024 Common Shares 18,334 $3.00 Direct F3
holding LEXX Stock Options 64,668 26 Apr 2024 Common Shares 15,000 $3.00 Direct F4
holding LEXX Stock Options 94,668 26 Apr 2024 Common Shares 30,000 $2.91 Direct
holding LEXX Stock Options 124,668 26 Apr 2024 Common Shares 30,000 $1.15 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023
F2 Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
F3 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F4 Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023